Medicare Enrolled

Dr. Amol Rao, M.D.

Hematology & Oncology · Fountain Valley, CA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Consulting-driven
18111 BROOKHURST ST STE 6100, Fountain Valley, CA 92708
7143787330
In practice since 2007 (18 years)
NPI: 1689871154 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Rao from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Rao? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Rao

Dr. Amol Rao is a hematology & oncology specialist in Fountain Valley, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Rao performed 20,859 Medicare services across 315 unique beneficiaries.

Between the years covered by Open Payments, Dr. Rao received a total of $50,538 from 65 pharmaceutical and/or device companies across 407 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Rao is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 18 years in practice ▲ Top 23% volume in CA $50,538 industry payments

Medicare Practice Summary

Medicare Utilization ↗
20,859
Medicare services
Top 23% in CA for hematology & oncology
315
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,159 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Iron infusion (Feraheme)
An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis.
13,770 $0 $3
Denosumab injection (Prolia/Xgeva) 5,820 $18 $41
Dexamethasone injection (steroid)
An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram.
568 $0 $3
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
195 $12 $60
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
130 $60 $203
Intravenous injection of additional new drug or substance
Administration of an additional new medication or substance directly into a vein.
93 $14 $53
Vitamin B-12 injection
An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg.
57 $1 $8
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
53 $124 $428
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
46 $60 $170
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
43 $106 $288
Blood draw (venipuncture)
Insertion of a needle into a vein to collect a blood sample.
36 $6 $6
Additional sequential IV infusion, 1 hour or less
This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less.
35 $27 $74
New patient office visit, complex (60-74 min) 13 $170 $488
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
66.7% high complexity
32.3% medium
1.1% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$50,538
Total received (2018-2024)
Avg $7,220/year across 7 years
Top 12% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
65
Companies
407
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$40,926 (81.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,502 (14.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$2,110 (4.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$36,176
2023
$286
2022
$916
2021
$1,664
2020
$1,259
2019
$3,477
2018
$6,759

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Tempus AI, Inc
$35,126
AstraZeneca Pharmaceuticals LP
$1,050
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
Tempus AI, Inc
$35,126
Kite Pharma, Inc.
$3,556
AstraZeneca Pharmaceuticals LP
$1,668
Daiichi Sankyo Inc.
$750
Merck Sharp & Dohme Corporation
$748
Astellas Pharma US Inc
$735
E.R. Squibb & Sons, L.L.C.
$610
Genentech USA, Inc.
$541
GENZYME CORPORATION
$533
Novartis Pharmaceuticals Corporation
$463
SANOFI-AVENTIS U.S. LLC
$350
Incyte Corporation
$303
Takeda Pharmaceuticals U.S.A., Inc.
$294
Pharmacyclics LLC, An AbbVie Company
$291
Janssen Biotech, Inc.
$257
COMSORT, Inc
$250
Amgen Inc.
$248
PFIZER INC.
$238
Bayer HealthCare Pharmaceuticals Inc.
$212
Novocure GmbH
$200
Celgene Corporation
$191
Exelixis Inc.
$181
Athenex Pharmaceutical Division, LLC
$175
EMD Serono, Inc.
$159
Teva Pharmaceuticals USA, Inc.
$150
TESARO, Inc.
$150
Foundation Medicine, Inc.
$145
Janssen Scientific Affairs, LLC
$141
AbbVie, Inc.
$131
Ipsen Biopharmaceuticals, Inc
$111
BeiGene USA, Inc.
$111
Puma Biotechnology, Inc.
$99
Seattle Genetics, Inc.
$98
Gilead Sciences, Inc.
$89
TerSera Therapeutics LLC
$87
Regeneron Healthcare Solutions, Inc.
$85
Janssen Pharmaceuticals, Inc
$68
EISAI INC.
$67
CSL Behring
$67
Lilly USA, LLC
$66
Seagen Inc.
$62
Alexion Pharmaceuticals, Inc.
$59
Clovis Oncology, Inc.
$58
Boehringer Ingelheim Pharmaceuticals, Inc.
$54
Octapharma USA, Inc.
$52
Otsuka America Pharmaceutical, Inc.
$49
TOLMAR Pharmaceuticals, Inc.
$40
Heron Therapeutics, Inc.
$36
Helsinn Therapeutics (U.S.), Inc.
$35
MEDIVATION FIELD SOLUTIONS LLC
$32
Eisai Inc.
$32
Sirtex Medical Inc
$30
ARRAY BIOPHARMA INC
$25
AMAG Pharmaceuticals, Inc.
$25
Myriad Genetic Laboratories, Inc.
$22
AbbVie Inc.
$22
Mylan Pharmaceuticals Inc.
$21
Fortovia Therapeutics, Inc.
$21
Mirati Therapeutics, Inc.
$21
Mylan Institutional Inc.
$19
Dendreon Pharmaceuticals LLC
$18
Dova Pharmaceuticals
$17
Coherus Biosciences Inc.
$15
INSYS Therapeutics Inc
$14
Taiho Oncology, Inc.
$13
Top 3 companies account for 79.8% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AKYNZEO · ALIMTA · ALOXI · Abraxane · Afstyla · Alecensa · Aliqopa · Avastin · BENDEKA · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CALQUENCE · CHANTIX · CINVANTI · CYRAMZA · Cabometyx · DARZALEX · Doptelet · ELIGARD · ELIQUIS · ELITEK · EMPLICITI · Erleada · FASLODEX · FERAHEME · FOUNDATIONONE · Fulphila · GILOTRIF · GRANIX · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · Idelvion · Imbruvica · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LENVIMA · LIBTAYO · LUTATHERA · Lenvima · Lonsurf · MEKINIST · MONJUVI · MYLOTARG · NERLYNX · NINLARO · NUWIQ · Nerlynx · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONUREG · OPDIVO · PADCEV · PIQRAY · PROMACTA · PROVENGE · Perjeta · Pomalyst · Prolia · Revlimid · Rubraca · SARCLISA · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYNDROS · Somatuline Depot · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TUKYSA · Udenyca · Ultomiris · VARUBI · VENCLEXTA · VOTRIENT · Venclexta · XALKORI · XARELTO · XGEVA · XOSPATA · XT CDX · XTANDI · Xofigo · ZEJULA · ZOLADEX · myChoice CDx
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (81%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.

Looking for a hematology & oncology specialist in Fountain Valley?
Compare hematology & oncology specialists in the Fountain Valley area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
208
Per 100K population
6.6
County median income
$113,702
Nearest hospital
UCI HEALTH - FOUNTAIN VALLEY
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Rao is a mixed practice specialist, with above-average Medicare volume (top 23% in CA), with consulting-driven industry engagement in the top 12% of CA peers, with 18 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Rao experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Rao performed 13,770 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Rao receive payments from pharmaceutical companies?
Yes. Dr. Rao received a total of $50,538 from 65 companies across 407 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Rao's costs compare to other hematology & oncology specialists in Fountain Valley?
Dr. Rao's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Rao) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →